DK0792160T3 - Glial-afledt neurofoisk faktor som et neurobeskyttende middel - Google Patents

Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Info

Publication number
DK0792160T3
DK0792160T3 DK95935548T DK95935548T DK0792160T3 DK 0792160 T3 DK0792160 T3 DK 0792160T3 DK 95935548 T DK95935548 T DK 95935548T DK 95935548 T DK95935548 T DK 95935548T DK 0792160 T3 DK0792160 T3 DK 0792160T3
Authority
DK
Denmark
Prior art keywords
glial
derived
factor
neurophysical
gdnf
Prior art date
Application number
DK95935548T
Other languages
Danish (da)
English (en)
Inventor
David Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0792160T3 publication Critical patent/DK0792160T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95935548T 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel DK0792160T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15
PCT/IB1995/001004 WO1996014861A1 (en) 1994-11-15 1995-11-13 Glial derived neurotrophic factor as a neuroprotective agent

Publications (1)

Publication Number Publication Date
DK0792160T3 true DK0792160T3 (da) 2001-11-19

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935548T DK0792160T3 (da) 1994-11-15 1995-11-13 Glial-afledt neurofoisk faktor som et neurobeskyttende middel

Country Status (13)

Country Link
US (1) US5733875A (de)
EP (1) EP0792160B1 (de)
JP (1) JPH10508839A (de)
AT (1) ATE205088T1 (de)
AU (1) AU691349B2 (de)
CA (1) CA2204911C (de)
DE (1) DE69522578T2 (de)
DK (1) DK0792160T3 (de)
ES (1) ES2159647T3 (de)
IL (1) IL115966A (de)
PT (1) PT792160E (de)
WO (1) WO1996014861A1 (de)
ZA (1) ZA959714B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
NZ335207A (en) 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
WO2001030375A2 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
PL2019683T5 (pl) 2006-04-25 2022-12-05 The Regents Of The University Of California Podawanie czynników wzrostu do leczenia zaburzeń OUN
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
EP3973979A1 (de) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Tight-junction (zonulae occludentes)-protein zur verwendung in der behandlung oder vorbeugung einer neurologischen störung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
IL115966A0 (en) 1996-01-31
ES2159647T3 (es) 2001-10-16
AU691349B2 (en) 1998-05-14
DE69522578D1 (de) 2001-10-11
CA2204911A1 (en) 1996-05-23
CA2204911C (en) 2002-07-23
PT792160E (pt) 2002-02-28
ZA959714B (en) 1997-10-15
US5733875A (en) 1998-03-31
ATE205088T1 (de) 2001-09-15
JPH10508839A (ja) 1998-09-02
AU3752895A (en) 1996-06-06
WO1996014861A1 (en) 1996-05-23
EP0792160A1 (de) 1997-09-03
IL115966A (en) 1999-11-30
EP0792160B1 (de) 2001-09-05
DE69522578T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
ZA959714B (en) Methods of using GDNF as a neuroprotective agent.
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
MX9207495A (es) Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
HUP0003323A2 (hu) Vorikonazolt tartalmazó gyógyászati készítmények
DK0867179T3 (da) Sammensætning af L-DOPA-estere
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
MY119375A (en) Treatment of tinnitus using neuroprotective agents
MX9205466A (es) Procedimiento para la preparacion de un medicamento para la administracion oral o topica en el tratamiento de leishmaniasis
DE69631609D1 (en) Tricyclische erythromycinderivate
CA2459470A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
TW324662B (en) Benzamide-containing pharmaceutical composition
ATE319715T1 (de) Antikonvulsive pseudofructopyranose sulfamate
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
BR9809519A (pt) Sal, processo para fabricação e uso do mesmo, formulação farmacêutica, e, processo para prevenção ou tratamento de distúrbios cns e perturbações médicas relacionadas
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat